$ZYDUSLIFE

Zydus Therapeutics, the US-based specialty arm of $ZYDUSLIFE has announced positive results from its pivotal EPICS-III Phase 2b/3 trial evaluating Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease. The Ahmedabad-based drugmaker plans to file for USFDA approval in the first quarter of 2026, targetting a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%. The trial met its primary endpoint, with 48.5% of patients on Saroglitazar 1mg achieving a meaningful biochemical response compared with the placebo. The drug also met other key results including complete normalization of alkaline phosphatase (ALP), a critical marker of disease progression. The trial enrolled 149 patients across multiple centers and was designed as a seamless study. Full data will be presented at an upcoming scientific congress,